Synta Pharmaceuticals Announces Formation of Expert Oncology Panel

On October 8, 2015 Synta Pharmaceuticals Corp. (NASDAQ: SNTA) reported the formation of an Expert Oncology Panel to provide guidance on research and development strategies for the Company’s portfolio of novel oncology therapies (Press release, Synta Pharmaceuticals, OCT 8, 2015, View Source;p=RssLanding&cat=news&id=2095347 [SID:1234507676]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Inaugural members of Synta’s Expert Oncology Panel include:

David E. Avigan, M.D. – Chief Section of Hematological Malignancies and Bone Marrow Transplantation, Beth Israel Deaconess Medical Center Associate Professor, Medicine, Harvard Medical School
Bruce Allan Chabner, M.D. – Director of Clinical Research, Cancer Center Massachusetts General Hospital Cancer Center
Jeffrey A. Engelman, M.D., Ph.D. – Director, Center for Thoracic Cancers Massachusetts General Hospital Cancer Center, Associate Professor of Medicine Harvard Medical School
F. Stephen Hodi, Jr., M.D. – Director, Melanoma Center Director, Center for Immuno-Oncology, Associate Professor of Medicine Harvard Medical School, Dana Farber Cancer Institute
Martin J. Murphy, D. MedSc, Ph.D., FASCO – Chairman and Chief Executive Officer AlphaMed Consulting, Inc.
Neil Lee Spector, M.D. – Associate Professor of Medicine, Sandra Coates Associate Professor, Associate Professor of Pharmacology & Cancer Biology, Member of the Duke Cancer Institute

"It is our pleasure to welcome a group of world-renowned physicians and scientists to our newly formed Expert Oncology Panel," said Chen Schor, President and Chief Executive Officer of Synta. "We expect that this panel will lend important perspective in translating the breadth of emerging preclinical and clinical data with ganetespib into well designed clinical studies aimed at providing meaningful clinical benefits to cancer patients in selected indications. The advice of the panel will also be important in shaping our HDC program strategy as we move towards the clinic with the first candidate from this program, STA-12-8666, and consider additional payloads for development. This distinguished expert panel, together with our newly appointed Chief Scientific Officer, Dr. Alan Rigby, is taking Synta one step further in our mission to discover, develop and commercialize oncology medicines that change cancer patients lives."

Dr. Avigan is Professor, Department of Medicine, Harvard Medical School, Chief, Hematological Malignancy and Bone Marrow Transplant section at Beth Israel Deaconess Medical Center and a co-Clinical Leader of the Leukemia Program at the Dana Farber Harvard Cancer Center. He leads a translational research program for hematological malignancies with a focus on vaccine therapy, tumor immunology, and stem cell biology with a strong track record for clinical translation of biologic based treatments. Dr. Avigan earned his M.D. from Yale University School of Medicine, completed his residency at Columbia Presbyterian Medical Center in Internal Medicine, and his fellowship at Memorial Sloan-Kettering Cancer Center in Hematology/Oncology.

Dr. Chabner is the Clinical Director, Emeritus, and Paul G. Allen Scholar at the Massachusetts General Hospital Cancer Center. During his career at the National Cancer Institute (NCI), he served as a Senior Investigator in the Laboratory of Chemical Pharmacology, Chief of the Clinical Pharmacology Branch, Director of the Clinical Oncology Program, and Director of the Division of Cancer Treatment. At the NCI, he maintained an active laboratory program in cancer pharmacology, and led the development of Taxol. His research contributed significantly to the development of high dose chemotherapy regimens, and to standard therapies for lymphoma. Dr. Chabner is the Editor in Chief for The Oncologist and serves on the executive advisory boards for some of the industry’s leading innovators in drug development. In 2006, Dr. Chabner received a presidential appointment to the National Cancer Advisory Board at the NCI, which he chaired from 2010 to 2012. Dr. Chabner earned his M.D. at Harvard Medical School, completed his residency at Brigham and Women’s Hospital, and his fellowships at the NCI and Yale-New Haven Hospital.

Dr. Engelman is the Director, Center for Thoracic Cancers at the Massachusetts General Hospital Cancer Center and an Associate Professor of Medicine at the Harvard Medical School. The overarching aim of research in the Engelman laboratory at Mass General is to develop new and more effective therapeutic strategies for the treatment of cancer, with a particular emphasis on lung cancer. Dr. Engelman is board certified in medical oncology and earned his M.D. and Ph.D. from the Albert Einstein College of Medicine. He completed his residency at Brigham and Women’s Hospital and Fellowship at the Dana Farber Cancer Institute and Massachusetts General Hospital combined program.

Dr. Hodi is the Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women’s Cancer Center and Assistant Professor of Medicine at Harvard Medical School. He received his M.D. degree from Cornell University Medical College in 1992. Dr. Hodi competed his postdoctoral training in Internal Medicine at the Hospital of the University of Pennsylvania, and Medical Oncology training at Dana-Farber Cancer Institute where he joined the faculty in 1995. His research focuses on gene therapy, the development of immune therapies, and first into human studies for malignant melanoma. Dr. Hodi is a member of the National Comprehensive Cancer Network, the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), the Eastern Cooperative Oncology Group Melanoma Committee, the International Society for the Biological Therapy of Cancer, and a founding member of the Society for Melanoma Research.

Dr. Murphy is the Founding Chairman and Chief Executive Officer of AlphaMed Consulting, Inc., a consultancy that provides strategic support for academic cancer centers and cancer drug development programs of global pharmaceutical and biotechnology companies. He is the founding Executive Editor of three journals: The Oncologist, Stem Cells and of Stem Cells Translational Medicine. Dr. Murphy was founding Chief Executive Officer of Hipple Cancer Research Center and an NIH principal investigator who merited more than $25 million in competitive NIH grants. He is Co-founder of the Society for Translational Oncology, a member of the Scientific Advisory Board of Hatteras Venture Partners, a charter member of the International Advisory Board of Amsterdam’s VU University Medical Imaging Center, a charter member of Queen’s University-Belfast School of Medicine International Review Board, Chairman Emeritus of the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), convener of ACT-China, and Steering Committee Member and Senior Consultant of the Chinese Society of Clinical Oncology. He is also a member of the National Cancer Policy Forum of the National Academy of Medicine of the United States National Academy of Sciences, a director of the Foundation for the National Institutes of Health, a member of the Board of Visitors of the UNC Lineberger Comprehensive Cancer Center, a member of the Board of Advisors of the H. Lee Moffitt Cancer Center & Research Institute and a charter member and vice chairman of C-Change, founded by former President George H.W. Bush and former First Lady Barbara Bush. Dr. Murphy is a Fellow of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) and is Founding Chief Executive Officer of the non-profit CEO Roundtable on Cancer at the request of the Forty-First President George H.W. Bush.

Dr. Spector is the Sandra Coates Chair Breast Cancer Research at the Duke University Medical Center, Leader of the Developmental Therapeutics Program, Duke Cancer Institute, and currently serves as Scientific Advisor to Synta. Prior to joining Duke, Dr. Spector served as Director of GlaxoSmithKline’s Exploratory Medical Sciences in Oncology, where he successfully guided the development of Tykerb (lapatinib) and Arranon (nelarabine) from initial preclinical studies through clinical development and eventual FDA approval. Dr. Spector is board-certified in Hematology, Medical Oncology and Internal Medicine and earned his M.D. at the University of Medicine and Dentistry of New Jersey. He completed his residency in Internal Medicine at Parkland Memorial Hospital, University of Texas, Southwestern Medical Center and in Medical Oncology/Hematology at the Dana Farber Cancer Institute and Massachusetts General Hospital combined program.

Kite Pharma Commends Steven A. Rosenberg, M.D., Ph.D., on the Prestigious Medal of Honor Award From the American Cancer Society

On October 7, 2015 Kite Pharma, Inc. (Kite) (Nasdaq:KITE) reported that Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery at the National Cancer Institute (NCI) and a special advisor to Kite, has received three significant awards for his achievements and career dedicated to advancing cancer research (Press release, Kite Pharma, OCT 7, 2015, View Source [SID:1234507657]). The American Cancer Society (ACS), the largest voluntary health organization in the United States, awarded Dr. Rosenberg its Medal of Honor for his pioneering leadership in cancer immunotherapy. The Medal of Honor is the ACS’ highest honor and was presented to Dr. Rosenberg at a ceremony held in Washington, DC, on September 30, 2015. Additional recent awards include:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Rosenberg has been awarded the Samuel J. Heyman Service to America Medal for career achievement by the Partnership for Public Service. The "Sammies" are bestowed upon individuals to highlight excellence in the federal workforce and inspire other talented and dedicated individuals to go into public service. Dr. Rosenberg will receive his award during a gala and ceremony that is taking place tonight, October 7, in Washington, DC.

Susan G. Komen, the world’s largest breast cancer organization, awarded Dr. Rosenberg the Betty Ford Lifetime Achievement Award for his four decades of work in fighting cancer at the NCI. This award recognizes individuals who have committed their lives to engaging the public in the fight against breast cancer, advocating for meaningful change, and educating communities to support women and men facing the disease. Dr. Rosenberg was recognized during the Honoring the Promise gala, which took place in Washington, DC, on September 24, 2015.

In 2012, Kite partnered with Dr. Rosenberg and the NCI under a Cooperative Research and Development Agreement (CRADA) to further the research and development of multiple chimeric antigen receptor (CAR) and T cell receptor (TCR) based product candidates for the treatment of advanced solid and hematological malignancies. Many of these product candidates are now being assessed in clinical trials and Kite has since exclusively licensed intellectual property related to certain of these product candidates.

"We have always appreciated the great honor of being able to advance cancer therapies with Steve and are thrilled that three of the most prominent awards in medicine and public service have been made in recognition of the pivotal role Steve has played in cancer care and research on the national stage," said Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer of Kite. "During his long and successful career, Steve’s insights time and again have had an astounding impact on the direction of cancer research. His contributions, including to the exciting field of cancer immunotherapy, have been immense, and we are elated for Steve to receive these awards."

Cancer Research UK invests £15 million to unite finest minds across UK to develop better treatments

On October 7, 2015 Cancer Research UK reported that it has invested £15 million to inspire collaborative cancer research between scientists across the UK through a new awards scheme launched today (Press release, Cancer Research UK, OCT 7, 2015, View Source [SID:1234507659]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Effective partnerships are crucial for delivering the greatest science and boosting advancements in fighting cancer." – Dr David Scott

The Cancer Research UK Centres Network Accelerator Award is a new initiative which provides infrastructure support to research centres in order to encourage collaboration between different organisations and boost ‘bench to bedside’ science.

Four centres – Queens University Belfast (link is external), the University of Leicester (link is external), the Francis Crick Institute (link is external), and the University College London (link is external)– have each received a five-year grant.

Queens University Belfast* received £3.9 million to develop new pathology and image analysis techniques for solid tumours. This includes research to improve cancer diagnosis through tissue imaging, biomarker discovery, and clinical trials. The award will also invest in the next generation of scientists with a Clinical Fellowship programme in molecular pathology.

The University of Leicester** received £1.7 million to set up facilities to study structural biology among centres to improve drug development. The award will focus on research to translate the understanding of structural biology into drugs that could treat patients.

The Francis Crick Institute*** received £4.2 million to support more experimental cancer research and create Clinical Research Fellowships to help unite different research centres in London. This will help turn innovation in the laboratory into tangible benefits for patients – to save more lives from the disease in the future.

University College London**** received £5 million to help advance immunotherapy research – a field of cancer research which has shown promise for a long time and recently provided exciting breakthroughs in cancer treatments. The award will fund research to understand how patients develop immune responses – and why they stop responding to treatments. The award will also help scientists develop new therapies, and safe ways to give treatments.

Professor David Waugh, Director of the Centre for Cancer Research and Cell Biology at Queens University Belfast, said: "This award will allow us to accelerate the development of clinically-robust diagnostic tests that assist in personalizing cancer therapy. The network will help us set technology standards for this increasingly important and fast growing area of cancer research."

Professor Catrin Pritchard, science director at the Cancer Research UK Leicester Centre, said: "Personalised medicine is the future of cancer treatment, and by collaborating with centres across the UK, we look forward to accelerating research underpinning drug development."

Dr Richard Treisman, a research director at the Francis Crick Institute, said: "Thinking outside the box and collaborating across different disciplines and institutions is what we need to invigorate more innovative cancer research."

Professor Henning Walczak, scientific director of the Cancer Research UK – UCL Centre, said: "There has been great progress in the field of cancer immunotherapy and by collaborating with centres across London our Accelerator Network aims to bring successful cancer immunotherapies to more patients and to overcome some of the hurdles in this field."

Dr David Scott, Cancer Research UK’s director of science funding, said: "Effective partnerships are crucial for delivering the greatest science and boosting advancements in fighting cancer. We’re proud to invest in collaborative and innovative research across the UK with the new Centres Network Accelerator awards. It’s through working together and uniting expertise that we will do better research and save more lives."

Varian Announces U.S. Clearance and CE Mark for VitalBeam™ Package; Chirayu Medical College in Bhopal Acquires the New Platform for Advanced Radiotherapy

On October 7, 2015 Varian Medical Systems reported that the Chirayu Medical College and Hospital (CMCH) in Bhopal, India, is among the first cancer treatment centers around the world to acquire the new VitalBeam platform from Varian Medical Systems (NYSE: VAR), offering clinics a modular technology package for affordable, high-quality, high-throughput radiotherapy, and for expanding clinical capabilities over time (Press release, InfiMed, OCT 7, 2015, View Source [SID:1234507660]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The VitalBeam radiotherapy treatment platform from Varian Medical Systems
Varian recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) as well as the CE Mark for the VitalBeam platform. In addition to the CMCH in India, treatment centers in the U.S. and Europe have now ordered the system, which incorporates many of the innovations Varian developed to enhance the precision, safety, and speed of treatment on its popular TrueBeam radiotherapy system.

The VitalBeam system at the CMCH will anchor a new radiotherapy department there, complementing existing medical oncology services. "We are looking to increase the capacity in our region for helping cancer patients with the most advanced treatments possible and we are making efforts to provide patients with the best available treatments in the world," said Ajay Goenka, M.D., owner of CMCH. "We chose VitalBeam because we wanted something with the advantages of the TrueBeam platform that would enable us to go beyond basic intensity-modulated radiotherapy."

"The VitalBeam system will enable us to complete image-guided treatments quickly—in as little as 2-4 minutes when using advanced capabilities like RapidArc—and to shape the radiation dose very precisely," added T. P. Sahoo, M.D., physician at the CMCH. "That will be good news for the cancer patients of our region."

According to Dr. Sahoo, the clinical team at the CMCH will use the VitalBeam system to treat patients with tumors in vital locations where toxicity to healthy tissues must be minimized. "I anticipate that we will use it curatively, to treat head and neck, brain, pancreatic, and other abdominal malignancies, because these are common cancers that can be addressed with advanced radiotherapy."

"Our goal, with this platform, was to help increase access to quality cancer care around the world," said Kolleen Kennedy, president of Varian’s Oncology Systems business. "We are gratified to work with institutions like the Chirayu Medical College in bringing advanced, image-guided radiotherapy to more cancer patients."

Myriad Genetics and Tufts Health Plan Sign Agreement to Cover Prolaris(R) for Members With Localized Prostate Cancer

On October 7, 2015 Myriad Genetics, Inc. (NASDAQ:MYGN) reported that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris for members diagnosed with localized prostate cancer (Press release, Myriad Genetics, OCT 7, 2015, View Source [SID:1234507661]). Prolaris is the first and only biopsy test validated against prostate cancer specific mortality.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Tufts Health Plan is a leading health plan in the Northeast with more than one million members. Tufts Health Plan’s members will benefit from this agreement, which is designed to drive optimal treatment because men can confidently pursue active surveillance for tumors identified as being less aggressive with Myriad’s extensively validated Prolaris combined score. Recent data show that many men realize no benefit from interventional treatment, and many suffer needlessly from the side effects associated with radical prostatectomy and radiation.

"Myriad is excited to offer Prolaris testing to Tufts Health Plan’s members. We believe it will help to improve patient care and lower healthcare costs," said Nicole Lambert, general manager, Urology Business Unit, Myriad Genetic Laboratories. "The Prolaris test has been validated in multiple clinical studies and provides substantially stronger prognostic power than standard pathology. The Prolaris test enables physicians to confidently tailor treatment plans for their patients."

About Prolaris

Prolaris is a prognostic test that measures the expression level of genes involved with tumor proliferation to predict disease outcome. Prolaris is the only test that provides insight into meaningful oncologic endpoints by predicting 10-year prostate cancer-specific mortality, thereby guiding medical management. For more information visit: www.prolaris.com.